Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison
10.4137/CMO.S13671
Saved in:
Main Authors: | Tan, P.S., Haaland, B., Montero, A.J., Kyriakopoulos, C.E., Lopes, G. |
---|---|
Other Authors: | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE |
Format: | Article |
Published: |
2016
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/126501 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer
by: Kim C.S., et al.
Published: (2018) -
Dual inhibitory action of a novel akr1c3 inhibitor on both full-length ar and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer
by: Kafka, M., et al.
Published: (2021) -
ANTIANDROGEN ICARITIN ACTS AS A MODULATOR OF ANDROGEN RECEPTOR TO INHIBIT PROSTATE CANCER GROWTH
by: TAN MEI HUI EILEEN
Published: (2014) -
Application of Model-Informed Precision Dosing to Complex Clinical Scenarios in Oncology: Case Studies of Rivaroxaban and Abiraterone
by: CHEONG JING YI, ELEANOR
Published: (2021) -
Cutaneous reaction associated with weekly docetaxel administration
by: Chew, L., et al.
Published: (2014)